S4
CARDIOLOGY
No more,
half-finished treatments
virbac
S4 RILEXINE™ Palatable Tablets are the tasty solution for improved compliance and efficacy.
Studies confirm excellent
efficacy when administered
on superficial and deep
pyoderma compared to
Product A (amoxycillinclavulanic acid)at the
recommended dosage
of 12.5 mg/kg BID1.
Reference1: Gauguère E. et al.
Proceedings of the 3rd World Congress of
Veterinary Dermatology, Edinburgh, 1996.
Reference2: S4 RilexineTM 75 Palatable Tablets – Reg. No. A04/21.9/02. Each tablet contains Cephalexin monohydrate equivalent to 75 mg Cephalexin. S4 RilexineTM 300 Palatable Tablets – Reg. No. A04/21.9/03.
Each tablet contains Cephalexin monohydrate equivalent to 300 mg Cephalexin. S4 RilexineTM 600 Palatable Tablets – Reg. No. A04/21.9/04. Each tablet contains Cephalexin monohydrate equivalent to 600 mg
Cephalexin. For full product information refer to pakage insert.
Virbac RSA (Pty) Ltd (Reg. No. 1990/003743/07)
Private Bag X115, Halfway House, 1685
Republic of South Africa
Tel: (012) 657-6000
Fax: (012) 657-6067
JUNE 2016 Vet360 working.indd 35
6400Virb_Rilexine_Ad.indd 1
Issue 03 | JUNE 2016 | 35
Shaping the future of animal health.
2016/05/24 12:04 AM
2015/01/30 2:23 PM